Jul 11, 2022
Inaugural Webinar Session, Reimagining R&D Series presenting “Accelerating the Availability of Medication to Pediatric Patients.”
Vivpro Corporation is proud to announce the start of our webinar series “Reimagining R&D.” We’ve partnered with experts and industry leaders to discuss critical pharma and biotech topics. Our goal is to share valuable information and allow the audience to engage with questions while they receive real-time feedback.
For our inaugural session, we are joined by Dr. Allison Dunn, PharmD, MS, a Postdoctoral research fellow at the University of Maryland, Baltimore School of Pharmacy Center of Translational Medicine, and Dr. Lisa Bollinger, MD. Vice President at Merck.
Session Overview
The legislative history of pediatric drug development.
Principles of evidence generation, the role of extrapolation including modeling and simulation.
Tools to accelerate the generation of data in pediatric patients.
Case studies where extrapolation has played a pivotal role in pediatric patients’ labeling.
The 2030 strategic goals to accelerate the availability of medication to pediatric patients.
About Dr. Allison Dunn, PharmD, MS
Allison’s therapeutic areas of interest include infectious disease, metabolism/endocrinology, and neurology. Her research interest can be summarized as the use of pharmacometrics to support clinical trial design, dose optimization, and pediatric extrapolation. In the past, Allison has used population PKPD modeling, time-to-event modeling, and parent-metabolite modeling to answer clinical questions and assist in go-no-go decisions.
About Dr. Lisa Bollinger, MD
Pediatrician with over 20 years of leadership in drug development. She currently works at Merck in Global Regulatory Affairs and Clinical Safety as the Therapeutic Area Head of General Medicine and the U.S. Subsidiary. Before Merck, Dr. Bollinger worked in biotech at Amgen, where she held several leadership roles across regulatory and pharmacovigilance. Before Amgen, Lisa spent 13 years at the FDA in the Office of New Drugs as head of the Pediatric and Maternal Staff.
